ALKEM

Alkem Lab share price & financials

Price
₹5,373.5
Market cap
₹64.6k Cr
Sector
Healthcare
Calls analysed
7
Latest concall · Q1 FY27 · call held 20 Aug 2026

Alkem Lab Q1 FY27

Revenue from Operations ₹3,740 cr +11%EBITDA Margin 20.5%

What went well

  • Revenue from operations at INR3,740 crores, up 11% YoY.
  • International sales grew 16% YoY to INR1,222 crores.
  • Outperformed Indian pharmaceutical market by 100 basis points, with overall company growth of 13.2% vs IPM's 12.2%.

What to watch

  • Net profit saw a degrowth of 21.7% YoY due to taxation reasons.
  • Daman facility received an OAI status from the US FDA, though supplies continue uninterrupted.
Read the full call →

What Alkem Lab does

Alkem Laboratories is one of India's top-five pharmaceutical companies, operating across the value chain in branded generics, complex generics, biosimilars, APIs and nutraceuticals, with leadership positions in therapy areas such as anti-infectives, gastrointestinal, pain management and vitamins/minerals/nutrients. It earns primarily by manufacturing and selling formulations to doctors, hospitals, stockists and pharmacies in India (through a large field force) and via international subsidiaries such as Ascend Labs in the US, Australia, Latin America and Europe. Biosimilars are developed and manufactured through its subsidiary Enzene Biosciences, and in FY2025 the company entered the medical-devices business through Alkem MedTech, acquiring an orthopaedic-implants manufacturing facility and licensing premium implant technology.

Segments

  • Domestic Pharma
  • International Subsidiaries
  • API
  • Biosimilars
  • Wellness
  • MedTech
Countries with commercial presence
40+
Manufacturing facilities (incl. 6 USFDA-approved)
18
R&D centres
3
Medical representatives (field force)
12,500+
Brands
800+
SKUs
1,500+
Founded 1973Employees 21,000 (FY2024-25 (31 Mar 2025)) Company website

Guidance record · Q1 FY27

what the last two calls moved 23 tracked 5 delivered 3 missed 15 open
  • Occlutech Acquisition Closure delivered said Q4 FY26 Promised: within 45 to 60 days from May 28, 2026 Q1 FY27: Acquisition closed in mid-July 2026, within the guided 45-60 day timeline.
  • Tolvaptan US Launch went quiet said Q4 FY26 Promised: September or October 2026 Q1 FY27: No update provided on the launch timeline, with the target window of Sep/Oct 2026 approaching.
  • Effective Tax Rate FY27 revised down said Q4 FY26 Promised: 27% to 29% Q1 FY27: Guidance revised upwards to 30-32% at a consolidated level due to losses in subsidiaries where DTA is not recognized.

All 23 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 10.9%, net profit down 22.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue3,415 3,374 3,144 3,371 4,001 +17%3,737 +11%3,603 +15%3,740 +11%
EBITDA753 759 391 739 921 +22%828 +9%517 +32%766 +4%
Net profit702 641 322 668 779 +11%653 +2%251 −22%521 −22%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −4.4% 1Y

₹5.2k₹5.4k₹5.6k₹5.8kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 13 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 27 May 2026Q1 FY27 — 20 Aug 2026

1Y: ₹5,320.5 on 10 Sept 2025 → ₹5,087.5. High ₹5,890 (11 Feb 2026), low ₹5,087.5 (11 Sept 2026).

How the price took the results

close before → close after

Q1 FY27
+0.3%
20 Aug
Q4 FY26
+0.9%
28 May
Q3 FY26
−8.0%
13 Feb
Q2 FY26
−0.7%
13 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 8.2% a year over 3 years, FY23 to FY26. Operating margin widened to 20.4%.

Year endingFY23FY24FY25FY26
Revenue₹11.6k Cr₹12.7k Cr₹13.0k Cr₹14.7k Cr
Operating profit₹1.6k Cr₹2.2k Cr₹2.5k Cr₹3.0k Cr
Operating margin13.9%17.7%19.4%20.4%
Interest₹107 Cr₹112 Cr₹121 Cr₹161 Cr
Depreciation₹309 Cr₹299 Cr₹356 Cr₹383 Cr
Net profit₹1.0k Cr₹1.8k Cr₹2.2k Cr₹2.4k Cr
Net margin8.7%14.3%17.1%16.0%
Cash from operations₹1.7k Cr₹1.9k Cr₹1.9k Cr₹2.0k Cr
Free cash flow₹1.5k Cr₹1.8k Cr₹1.3k Cr₹1.5k Cr
ROCE14.0%20.0%20.0%21.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹24 Cr₹24 Cr₹24 Cr₹24 Cr₹24 Cr₹24 Cr
Reserves₹7.4k Cr₹8.6k Cr₹9.0k Cr₹10.3k Cr₹13.3k Cr₹13.8k Cr
Borrowings₹1.7k Cr₹2.7k Cr₹1.4k Cr₹1.4k Cr₹2.4k Cr₹2.0k Cr
Other liabilities₹2.4k Cr₹2.8k Cr₹3.3k Cr₹3.8k Cr₹4.6k Cr₹5.0k Cr
Total liabilities₹11.5k Cr₹14.1k Cr₹13.8k Cr₹15.6k Cr₹20.3k Cr₹20.9k Cr
Fixed assets₹2.8k Cr₹2.9k Cr₹2.7k Cr₹2.9k Cr₹3.3k Cr₹3.9k Cr
Capital work in progress₹393 Cr₹339 Cr₹323 Cr₹159 Cr₹653 Cr₹282 Cr
Investments₹333 Cr₹371 Cr₹622 Cr₹484 Cr₹2.5k Cr₹1.9k Cr
Other assets₹8.0k Cr₹10.5k Cr₹10.1k Cr₹12.1k Cr₹13.8k Cr₹14.8k Cr
Total assets₹11.5k Cr₹14.1k Cr₹13.8k Cr₹15.6k Cr₹20.3k Cr₹20.9k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters trimmed −3.34 pp while FIIs added +1.31 pp. The shareholder count shrank 21% to 62,822.

Promoters
49.7%
FIIs
10.4%
DIIs
22.6%
Public
17.3%

Since Jun 2025

  • Promoters −3.34 pp
  • FIIs +1.31 pp
  • Public +1.20 pp

How it drifted, 12 quarters

Over this window promoters fell from 56.7% to 49.7% — −7.0 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 56.7%, FIIs 6.0%, DIIs 17.6%, Public 19.6%.Dec '23: Promoters 56.7%, FIIs 8.5%, DIIs 15.9%, Public 18.9%.Mar '24: Promoters 56.7%, FIIs 9.1%, DIIs 15.6%, Public 18.5%.Jun '24: Promoters 56.4%, FIIs 8.7%, DIIs 18.6%, Public 16.4%.Sep '24: Promoters 55.7%, FIIs 9.0%, DIIs 19.2%, Public 16.1%.Dec '24: Promoters 55.7%, FIIs 10.1%, DIIs 18.0%, Public 16.2%.Mar '25: Promoters 55.1%, FIIs 9.4%, DIIs 19.4%, Public 16.1%.Jun '25: Promoters 53.0%, FIIs 9.1%, DIIs 21.8%, Public 16.1%.Sep '25: Promoters 51.2%, FIIs 9.5%, DIIs 21.9%, Public 17.4%.Dec '25: Promoters 51.2%, FIIs 10.0%, DIIs 21.5%, Public 17.3%.Mar '26: Promoters 51.2%, FIIs 10.2%, DIIs 21.4%, Public 17.3%.Jun '26: Promoters 49.7%, FIIs 10.4%, DIIs 22.6%, Public 17.3%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 4 holders trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Alkem Lab above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Sarandhar Singh * (please refer notes) 18.29%−0.46 pp
Basudeo Narain Singh 7.27%unchanged
Mritunjay Kumar Singh 6.42%unchanged
Madhurima Singh& (please refer notes) 6.18%unchanged
HDFC Mutual Fund - HDFC Mid-Cap Fund Mutual fund4.77%+0.71 pp
ICICI Prudential Multi-Asset Fund Mutual fund3.57%+0.47 pp
Kishor Kumar Singh 2.49%unchanged
Alok Kumar 2.31%unchanged
Ashok Kumar 2.25%unchanged
Seema Singh 2.16%unchanged
Deepak Kumar Singh 2.01%unchanged
Archana Singh 2.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in ALKEM

Filings to Aug 2026

0 new, 12 added, 1 trimmed, 1 sold out — net +1.26 L shares (+2.0%).

Held by funds
₹3.6k Cr
28 schemes
Biggest holder
SBI Large and Midcap Fund
₹787 Cr · 1.9% of that fund
SchemeHoldingLast month
SBI Large and Midcap Fund SBI Mutual Fund₹787 Crheld
Nippon India Growth Mid Cap Fund Nippon India Mutual Fund₹656 Cr+0.67 L
HDFC Balanced Advantage Fund HDFC Mutual Fund₹264 Crheld
HDFC Large and Mid Cap Fund HDFC Mutual Fund₹260 Crheld
HDFC Multi Cap Fund HDFC Mutual Fund₹259 Crheld
HDFC Hybrid Equity Fund HDFC Mutual Fund₹230 Crheld
HDFC ELSS Tax saver HDFC Mutual Fund₹201 Cr+0.40 L
Nippon India Pharma Fund Nippon India Mutual Fund₹173 Crheld

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Aug 2026

12 added, 1 trimmed — net +1.26 L shares (+2.0%)

Funds are sitting on
+11%
vs est. average cost
Held by funds
₹3.6k Cr
28 schemes · ≈ 5.4% of the company
Biggest holder
SBI Large and Midcap Fund
₹787 Cr · 1.9% of that fund
Longest holder
Nippon India Pharma Fund
9y 2m · since Jul '17

Shares held by these funds +113%

Aug '23 64.74 L shares Jul '26

What the price assumes

Attractive

To justify its price of ₹5088, this stock must grow earnings at 20% every year for 7 years. Our analysis caps realistic growth at ~33%. At that growth it is worth ₹9543 — upside of 88%.

Growth the price implies
20.1% a year
for 7 years, fading to 4%
It has actually compounded at
32.7% a year
net profit, FY23–FY26 · EPS 32.7%
The gap
-0.1 pp
88% downside if it only repeats history
Price today ₹5,087.5 Value at the reference growth ₹9,542.52

Change the assumptions yourself →

All earnings calls (7)

Read the Q1 FY27 call →

Learn to analyse Alkem Lab

Guides on how to read this kind of business and the numbers that matter.